Disse sidene inneholder informasjon som er beregnet på helsepersonell

Du forlater nå hjernenett.no

Digital produktpresentasjon av RXULTI®

Videopresentasjonen gir en introduksjon av RXULTI® (brekspiprazol); et antipsykotikum i tablettform til behandling av voksne pasienter med schizofreni.

Les mer: RXULTI®SPC

Ler mer: bivirkningsrapportering

 

NO-RXU-2100004 Sept2021

NO-REXU-0031

  1. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015;164:127–35.

  2. Correll C, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015;172:870–80.

  3. Corell C, Skuban A, Hobart M, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res 2016;174:82–92.

  4. Kane JM, Skuban A, Hobart M, et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res 2016;174:93–8.

  5. Fleischhacker WW, Hobart M, Ouyang, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2016;20:11–21.

  6. RXULTI® SPC 07/2020, avsnitt 4.1.

  7. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014;350:589–604.

  8. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 2003;28:1400–11.

  9. Gründer G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60:974-977.

  10. RXULTI® SPC 07/2020.

  11. Forbes A, Hobart M, Ouyang J, et al. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol 2018;21:433-41.

  12. RXULTI® SPC 07/2020, avsnitt 4.8.

  13. RXULTI® SPC 07/2020, avsnitt 4.2.

  14. RXULTI® SPC 07/2020, avsnitt 5.1.

  15. RXULTI® SPC 07/2020, avsnitt 4.4.

  16. RXULTI® SPC 07/2020, avsnitt 5.2.

  17. RXULTI® SPC 07/2020, avsnitt 4.2.1.

Dato publisert 22.04.2021